Active Biotech AB (ACTI) - Total Assets
Based on the latest financial reports, Active Biotech AB (ACTI) holds total assets worth Skr17.00 Million SEK (≈ $1.83 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of Active Biotech AB to assess how comfortably operating cash covers total debt obligations.
Active Biotech AB - Total Assets Trend (2000–2024)
This chart illustrates how Active Biotech AB's total assets have evolved over time, based on quarterly financial data. See ACTI net assets for net asset value and shareholders' equity analysis.
Active Biotech AB - Asset Composition Analysis
Current Asset Composition (December 2024)
Active Biotech AB's total assets of Skr17.00 Million consist of 90.7% current assets and 9.3% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr27.39 Million | 63.4% |
| Accounts Receivable | Skr9.50 Million | 22.0% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr3.35 Million | 7.8% |
| Intangible Assets | Skr245.00K | 0.6% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2000–2024)
This chart illustrates how Active Biotech AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Active Biotech AB worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Active Biotech AB's current assets represent 90.7% of total assets in 2024, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 63.4% of total assets in 2024, up from 11.5% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 5.0% in 2000.
- Asset Diversification: The largest asset category is cash and equivalents at 63.4% of total assets.
Active Biotech AB Competitors by Total Assets
Key competitors of Active Biotech AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
Active Biotech AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.17 | 0.93 | 3.24 |
| Quick Ratio | 1.17 | 1.31 | 3.27 |
| Cash Ratio | 0.75 | 0.54 | 0.00 |
| Working Capital | Skr2.10 Million | Skr-800.00K | Skr20.93 Million |
Active Biotech AB - Advanced Valuation Insights
This section examines the relationship between Active Biotech AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 22.61 |
| Latest Market Cap to Assets Ratio | 2.40 |
| Asset Growth Rate (YoY) | -1.9% |
| Total Assets | Skr43.20 Million |
| Market Capitalization | $103.60 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Active Biotech AB's assets at a significant premium (2.40x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Active Biotech AB's assets decreased by 1.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Active Biotech AB (2000–2024)
The table below shows the annual total assets of Active Biotech AB from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr43.20 Million ≈ $4.65 Million |
-1.92% |
| 2023-12-31 | Skr44.05 Million ≈ $4.74 Million |
-13.64% |
| 2022-12-31 | Skr51.01 Million ≈ $5.49 Million |
-10.21% |
| 2021-12-31 | Skr56.80 Million ≈ $6.11 Million |
+76.66% |
| 2020-12-31 | Skr32.16 Million ≈ $3.46 Million |
-51.97% |
| 2019-12-31 | Skr66.95 Million ≈ $7.21 Million |
-77.86% |
| 2018-12-31 | Skr302.43 Million ≈ $32.55 Million |
-0.45% |
| 2017-12-31 | Skr303.81 Million ≈ $32.70 Million |
-26.42% |
| 2016-12-31 | Skr412.88 Million ≈ $44.43 Million |
-8.14% |
| 2015-12-31 | Skr449.44 Million ≈ $48.37 Million |
-37.80% |
| 2014-12-31 | Skr722.52 Million ≈ $77.75 Million |
-5.90% |
| 2013-12-31 | Skr767.81 Million ≈ $82.63 Million |
+10.20% |
| 2012-12-31 | Skr696.74 Million ≈ $74.98 Million |
-18.84% |
| 2011-12-31 | Skr858.52 Million ≈ $92.39 Million |
+70.65% |
| 2010-12-31 | Skr503.10 Million ≈ $54.14 Million |
+0.92% |
| 2009-12-31 | Skr498.50 Million ≈ $53.65 Million |
+5.40% |
| 2008-12-31 | Skr472.95 Million ≈ $50.90 Million |
-3.39% |
| 2007-12-31 | Skr489.54 Million ≈ $52.68 Million |
+5.87% |
| 2006-12-31 | Skr462.40 Million ≈ $49.76 Million |
-18.57% |
| 2005-12-31 | Skr567.86 Million ≈ $61.11 Million |
+81.49% |
| 2004-12-31 | Skr312.89 Million ≈ $33.67 Million |
-9.41% |
| 2003-12-31 | Skr345.40 Million ≈ $37.17 Million |
-26.12% |
| 2002-12-31 | Skr467.50 Million ≈ $50.31 Million |
-37.48% |
| 2001-12-31 | Skr747.74 Million ≈ $80.47 Million |
-13.95% |
| 2000-12-31 | Skr868.95 Million ≈ $93.51 Million |
-- |
About Active Biotech AB
Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat relapsed refractory multiple myeloma; Laquinimod, a mechanism which is in phase 1 for the treatment of severe inflammatory eye diseases, such as… Read more